Capravirine

Capravirine

SCHEMBL40347

CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

pol

The experimentally established mechanism targets of Capravirine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35
P2RX3 P56373 6/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
TLR7 Q9NYK1 1/20 0.31
KCNH2 Q12809 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MAPT P10636 1/20 0.31
ENPP2 Q13822 1/20 0.30
SLC16A3 O15427 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HSP90B1 P14625 1/20 0.30
TRAP1 Q12931 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Capravirine SCHEMBL4656686 1.00 PIM1 (0.35) PIM1PIM3P2RX3MEN1KMT2A
SCHEMBL597334 0.92 P2RX3 (0.33) PIM1PIM3P2RX3MEN1KMT2A
SCHEMBL6961932 0.92 PIM1 (0.33) PIM1PIM3P2RX3MEN1KMT2A
SCHEMBL6964425 0.92 THRB (0.32) PIM1PIM3MAPTLMNAHSP90B1
SCHEMBL6960281 0.92 PIM1 (0.36) PIM1PIM3P2RX3KMT2ATDP1
SCHEMBL6967638 0.91 TDP1 (0.39) P2RX3MEN1KMT2ATLR7TDP1
SCHEMBL5852655 0.91 P2RX3 (0.33) PIM1PIM3P2RX3MEN1KMT2A
SCHEMBL14001658 0.91 P2RX3 (0.35) P2RX3TDP1MAPTENPP2
SCHEMBL6973396 0.91 PIM1 (0.34) PIM1PIM3P2RX3MEN1KMT2A
SCHEMBL13996465 0.91 P2RX3 (0.41) P2RX3KDM4EALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5755 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-12564595-B2 Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent SHIONOGI & CO., LTD. (JP) 2026-03-03 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4566670-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2025-06-11 EP claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
CN-119838022-A Amatoxin conjugates containing branched linkers 杭州多禧生物科技有限公司 2025-04-18 CN claimed
US-12220464-B2 Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-02-11 US claimed
US-20030096012-A1 Film-forming powder, compositions containing it, methods for their preparation and their uses GALENIX INNOVATIONS (FR) 2003-05-22 US claimed
EP-1295879-A1 MEDICINAL COMPOSITIONS CONTAINING PROPENONE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2003-03-26 EP claimed
WO-2002070470-A2 BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE SMITHKLINE BEECHAM CORPORATION (US) 2002-09-12 WO claimed
US-20020103378-A1 Method for carbamoylating alcohols ELLIS JAMES E (US) 2002-08-01 US claimed
EP-1172097-A1 PROCESS FOR PRODUCING MEDICINAL COMPOSITION OF BASIC HYDROPHOBIC MEDICINAL COMPOUND SHIONOGI & CO., LTD. (JP) 2002-01-16 EP claimed
US-6194391-B1 CS-87 (TITLE COMPOUND) INDUCES A TRANSIENT MUTATION IN HIV-1 AT THE 70TH CODON OF THE REVERSE TRANSCRIPTASE REGION OF THE VIRUS; ADMINISTERING TO A HUMAN IN NEED OF THERAPY WITH A DRUG THAT INDUCES A MUTATION IN HIV-1 AT ANOTHER LOCATION EMORY UNIVERSITY 2001-02-27 US claimed
US-6083958-A ADMINISTERING 2-CARBAMOYLOXYMETHYL-5-(3,5-DICHLOROPHENYLTHIO)-4-ISOPROPYL-1-(PYRIDIN-4 -YL)METHYL-1H-IMIDAZOLE OR THE PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANOTHER ANTI-HIV COMPOUND SHIONOGI & CO., LTD. (JP) 2000-07-04 US claimed
US-5910506-A IMIDAZOLE DERIVATIVES, E.G.5-(3,5-DICHLOROPHENYLTHIO)-1,2-DIMETHYL-4-ISOPROPYL-1H-IMIDAZOLE; VIRICIDES; AIDS; NONTOXIC SHIONOGI & CO., LTD. (JP) 1999-06-08 US claimed
EP-0906756-A1 ANTI-HIV COMPOSITION CONTAINING IMIDAZOLE DERIVATIVE SHIONOGI & CO., LTD. (JP) 1999-04-07 EP claimed
EP-0786455-A1 IMIDAZOLE DERIVATIVE SHIONOGI & CO., LTD. (JP) 1997-07-30 EP claimed